|
CYP2E1, CYP2C19, CYP2D6, mEH and NAT2 genotype frequencies in control subjects and in patients with breast carcinoma. |
||||||||||||||
| Genotypes |
Controls |
All Patients |
Premenopausal Patients |
Postmenopausal Patients |
||||||||||
| n |
f |
n |
f |
P |
OR (95%CI) |
n |
f |
p |
OR (95%CI) |
n |
f |
p |
OR (95%CI) |
|
|
|
||||||||||||||
| CYP2E1 (C-1091T) |
244 |
304 |
192 |
111 |
||||||||||
| CYP2E1 (C/C) |
232 |
0.95 |
296 |
0.97 |
N.S |
1.91(0.72–5.22) |
186 |
0.97 |
N.S |
1.6(0.55–4.89) |
109 |
0.98 |
N.S |
2.82(0.58–18.57) |
| CYP2E1 (C/T) |
12 |
0.05 |
08 |
0.03 |
N.S |
0.52(0.19–1.4) |
06 |
0.03 |
N.S |
0.62(0.2–1.83) |
02 |
0.02 |
N.S |
0.35(0.05–1.71) |
| CYP2E1 (T/T) |
00 |
0.00 |
00 |
0.00 |
N.S |
- |
00 |
0.00 |
N.S |
- |
00 |
0.00 |
N.S |
- |
|
|
||||||||||||||
| CYP2C19 (exon5 G-A) |
240 |
304 |
193 |
109 |
||||||||||
| CYP2C19 (G/G) |
197 |
0.822 |
239 |
0.787 |
N.S |
0.8(0.51–1.26) |
155 |
0.804 |
N.S |
0.89(0.53–1.49) |
83 |
0.762 |
N.S |
0.7(0.39–1.25) |
| CYP2C19 (A/G) |
41 |
0.170 |
61 |
0.200 |
N.S |
1.22(0.77–1.93) |
37 |
0.191 |
N.S |
1.15(0.68–1.94) |
23 |
0.211 |
N.S |
1.30(0.71–2.38) |
| CYP2C19 (A/A) |
02 |
0.008 |
04 |
0.013 |
N.S |
1.59(0.25–12.56) |
01 |
0.005 |
N.S |
0.62(0.02–8.76) |
03 |
0.027 |
N.S |
3.37(0.45–29.24) |
|
|
||||||||||||||
| CYP2D6 (G1934A) |
230 |
300 |
189 |
109 |
||||||||||
| CYP2D6 (G/G) |
167 |
0.726 |
235 |
0.783 |
N.S |
1.36(0.9–2.07) |
145 |
0.767 |
N.S |
1.24(0.78–1.99) |
90 |
0.827 |
0.04 |
1.79(0.97–3.31) |
| CYP2D6 (G/A) |
56 |
0.243 |
58 |
0.193 |
N.S |
0.74(0.48–1.15) |
41 |
0.217 |
N.S |
0.86(0.53–1.42) |
15 |
0.137 |
0.02 |
0.5(0.25–0.96) |
| CYP2D6 (A/A) |
07 |
0.031 |
07 |
0.023 |
N.S |
0.76(0.24–2.48) |
03 |
0.016 |
N.S |
0.51(0.1–2.24) |
04 |
0.036 |
N.S |
1.21(0.29–4.74) |
|
|
||||||||||||||
| mEH (T348C) |
244 |
306 |
194 |
110 |
||||||||||
| mEH1 (Tyr/Tyr) |
113 |
0.463 |
149 |
0.486 |
N.S |
1.1(0.77–1.56) |
97 |
0.500 |
N.S |
1.16(0.78–1.72) |
52 |
0.472 |
N.S |
1.04(0.65–1.67) |
| mEH2 (Tyr/His) |
115 |
0.471 |
119 |
0.388 |
N.S |
0.71(0.5–1.02) |
70 |
0.360 |
0.02 |
0.63(0.42–0.95) |
47 |
0.427 |
N.S |
0.84(0.52–1.35) |
| mEH3 (His/His) |
16 |
0.065 |
38 |
0.124 |
0.02 |
2.02(1.06–3.89) |
27 |
0.139 |
0.01 |
2.3(1.15–4.64) |
11 |
0.1 |
N.S |
1.58(0.66–3.77) |
|
|
||||||||||||||
| NAT2 |
237 |
290 |
184 |
105 |
||||||||||
| Rapid Acetylators |
14 |
0.059 |
24 |
0.082 |
N.S |
1.44(0.69–3) |
18 |
0.097 |
N.S |
1.73(0.79–3.79) |
06 |
0.057 |
N.S |
0.97(0.32–2.79) |
| Intermediate Acetylators |
105 |
0.443 |
92 |
0.317 |
N.S |
0.58(0.4–0.85) |
61 |
0.331 |
N.S |
0.62(0.41–0.95) |
30 |
0.285 |
0.006 |
0.52(0.3–0.85) |
| Slow Acetylators |
118 |
0.497 |
174 |
0.600 |
0.01 |
1.51(1.05–2.17) |
105 |
0.570 |
N.S |
1.34(0.89–2.01) |
69 |
0.657 |
0.006 |
1.93(1.17–3.2) |
|
The chi-square test was used to determine whether significant differences (p value) were observed when the patient group was compared with the control group. f, frequencies; NS: not significant. | ||||||||||||||
Khedhaier et al. BMC Cancer 2008 8:109 doi:10.1186/1471-2407-8-109 |
||||||||||||||